{"id":"NCT01324570","sponsor":"Purdue Pharma LP","briefTitle":"Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children","officialTitle":"An Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Buprenorphine Transdermal System (BTDS) in Children From 7 to 16 Years of Age, Inclusive, Who Require Continuous Opioid Analgesia for Moderate to Severe Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2016-05","completion":"2016-05","firstPosted":"2011-03-29","resultsPosted":"2017-07-06","lastUpdate":"2017-07-06"},"enrollment":41,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal system","otherNames":["Butrans"]}],"arms":[{"label":"Overall BTDS","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to characterize the safety, PK, and efficacy of BTDS in patients of ages 7 to 16 years.","primaryOutcome":{"measure":"The Number of Participants With Adverse Events as a Measure of Safety","timeFrame":"Up to 28 weeks","effectByArm":[{"arm":"7 to 11 Years","deltaMin":5,"sd":null},{"arm":"12 to 16 Years","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":6},"commonTop":["Nausea","Application Site Pruritus","Headache","Somnolence","Application Site Irritation"]}}